Source comparison
Thymosin Alpha-1 Half Life: Administration Method Comparison
Subcutaneous injection is the standard route of administration for thymosin alpha-1 research, but pharmacokinetic studies have tested intravenous, intramuscular, and even oral formulations. Each route alters the thymosin alpha-1 half life and bioavailability p
This comparison does not assign a generated winner or score.
- Subcutaneous injection is the standard route of administration for thymosin alpha-1 research, but pharmacokinetic studies have tested intravenous, intramuscular, and even oral formulations. Each route alters the thymosin alpha-1 half life and bioavailability profile significantly.
- Subcutaneous (SC)
- ~80–90%
- 30–60 minutes
- 2–3 hours (alpha phase)
- 48–72 hours sustained T-cell count elevation
- Standard for research protocols. Predictable absorption kinetics, minimal injection site reaction, twice-weekly dosing achieves stable immune modulation
- Intravenous (IV)
- 100%
- Immediate (within 5 min)
- 1.5–2 hours (faster renal clearance)
- 24–48 hours (shorter than SC due to rapid peak-and-drop pattern)
- Rarely used outside acute clinical settings. Higher Cmax but shorter duration of immune effect, requires medical supervision, no practical advantage over SC for multi-week protocols
- Intramuscular (IM)
- ~70–85%
- 45–90 minutes
- 2.5–3.5 hours
- 48–72 hours
- Slower absorption than SC with higher injection discomfort. No pharmacokinetic benefit to justify the route, used in early trials before SC became standard
- Oral (experimental)
- <5% (degraded by gastric enzymes)
- Not applicable
- Not measurable
- No detectable immune modulation in published trials
- Thymosin alpha-1 is a peptide. Gastric proteases cleave it into inactive fragments before intestinal absorption, oral bioavailability is effectively zero without enteric coating or permeation enhancers
- Subcutaneous administration at 1.6 mg twice weekly remains the evidence-supported standard. Intravenous bolus produces higher immediate plasma concentrations but faster renal elimination. The thymosin alpha-1 half life shortens to approximately 1.5 hours with IV dosing because the peptide bypasses subcutaneous absorption kinetics and enters circulation at saturating concentrations, triggering more rapid glomerular filtration. The tradeoff is a sharper peak with a faster drop, reducing the sustained TLR9 stimulation window that drives T-cell differentiation.
- Oral thymosin alpha-1 formulations have been marketed as supplements, but the peptide's bioavailability via this route is negligible. Gastric pH and pepsin activity cleave thymosin alpha-1 into dipeptides and tripeptides within minutes of ingestion. A study in Peptides demonstrated that oral thymosin alpha-1 at doses up to 10 mg produced no detectable plasma levels and no measurable change in CD4/CD8 ratios. The peptide was completely degraded before reaching systemic circulation. The thymosin alpha-1 half life is irrelevant if bioavailability is zero.